Please assess the completion status of the following clinical trial:

Trial Title: Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Tolerant AAV participants:~* Age 18 years or older~* Diagnosis of granulomatosis with polyangiitis (Wegener's, GPA) or microscopic polyangiitis (MPA) according to the definitions of the Chapel Hill Consensus Conference (CHCC)~* History of being myeloperoxidase (MPO)-ANCA positive during a disease flare~* In clinical remission with Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) = 0 and off all immunosuppression for ≥ 2 years~* Negative MPO-ANCA and proteinase 3 (PR3)-ANCA by ELISA at screening~* For women of child-bearing potential, a negative urine or serum pregnancy test at the time of screening~* Ability to sign and understand informed consent~* Willingness to comply with study procedures.~Non-Tolerant AAV participants:~* Age 18 years or older~* Diagnosis of granulomatosis with polyangiitis (Wegener's), GPA or microscopic polyangiitis (MPA) according to the definitions of the CHCC~* History of being MPO-ANCA positive during a disease flare~* Within the past 5 years, must have had a disease exacerbation, defined as an increase in the BVAS/WG score and re-institution of immunosuppressive therapy after therapy had been reduced or completely discontinued~* In clinical remission with BVAS/WG = 0 and on minimal maintenance therapy for ≥3 months prior to the screening visit. Minimal maintenance therapy is defined as:~  * Low-dose glucocorticoids (≤10 mg of prednisone or prednisolone daily) and/or:~    * Azathioprine ≤ 150mg daily or~   * Mycophenolate mofetil (MMF) ≤ 1 gram daily or mycophenolate sodium ≤ 720 mg daily.~* Positive MPO-ANCA by ELISA on at least 2 occasions within the last 52 weeks, the most recent result being within 8 weeks of visit -1~* For women of child-bearing potential, a negative urine or serum pregnancy test at the time of screening~* Ability to sign and understand informed consent~* Willingness to comply with study procedures.~Healthy Controls:~* Healthy participant age ≥18 years~* For women of child-bearing potential, a negative urine or serum pregnancy test at the time of screening~* Ability to sign and understand informed consent~* Willingness to comply with study procedures.~Exclusion Criteria:~Tolerant AAV Participants:~* Use of systemic intravenous (IV) or oral glucocorticoids for ˃ 1 month for any non-vasculitis indication within 8 weeks of the screening visit~* Any prior treatment with rituximab~* Presence of known chronic viral infections or autoimmune diseases~* History of malignancy, excluding non-melanomatous skin cancers or cervical cancer carcinoma in situ within 5 years of the screening visit.~Non-Tolerant AAV participants:~* Use of IV pulse glucocorticoids (methylprednisolone or other) or cyclophosphamide within the year prior to the screening visit~* Use of IV or oral glucocorticoids for \> 1 month for any non- vasculitis indication within 8 weeks of screening visit~* Any prior treatment with rituximab~* Maintenance therapy with methotrexate within 3 months of the screening visit~* Presence of known chronic viral infections or other autoimmune diseases~* History of malignancy, excluding non-melanoma skin cancers or cervical cancer carcinoma in situ within 5 years of the screening visit.~Healthy Controls:~* Use of IV or oral glucocorticoids for \> 1 month for any non-vasculitis indication within 8 weeks of the screening visit~* Presence of known chronic viral infections or other autoimmune diseases~* History of malignancy, excluding non-melanoma skin cancers or cervical cancer carcinoma in situ within 5 years of the screening visit.~AAV Participants Discontinuing Immunosuppression:~* Any prior treatment with rituximab~* Maintenance therapy with methotrexate within 3 months of the screening visit~* Presence of known chronic viral infections or other autoimmune diseases~* History of malignancy, excluding non-melanoma skin cancers or cervical cancer carcinoma in situ, within 5 years of the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tolerant AAV (Type: None): Tolerant participants with AAV
- Non-Tolerant AAV (Type: None): Non-Tolerant participants with ANCA-associated vasculitis (AAV)
- Healthy Controls (Type: None): Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
- AAV Discontinuing Immunosuppression (Type: None): Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues